Deciphera Pharmaceuticals Inc (DCPH) 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC TO-C - Written communication relating to an issuer or third party

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in...

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new...

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to...